Zobrazeno 1 - 10
of 289
pro vyhledávání: '"Mariateresa, Fulciniti"'
Autor:
Judith Lind, Osman Aksoy, Michaela Prchal-Murphy, Fengjuan Fan, Mariateresa Fulciniti, Dagmar Stoiber, Latifa Bakiri, Erwin F. Wagner, Elisabeth Zwickl-Traxler, Martin Sattler, Karoline Kollmann, Sonia Vallet, Klaus Podar
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Deregulation of transcription factors (TFs) leading to uncontrolled proliferation of tumor cells within the microenvironment represents a hallmark of cancer. However, the biological and clinical impact of transcriptional interference, partic
Externí odkaz:
https://doaj.org/article/6f0fada8d8aa46c2a07a49b9d5a5c9ab
Autor:
Moritz Binder, Raphael E. Szalat, Srikanth Talluri, Mariateresa Fulciniti, Hervé Avet-Loiseau, Giovanni Parmigiani, Mehmet K. Samur, Nikhil C. Munshi
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract The natural history of multiple myeloma is characterized by its localization to the bone marrow and its interaction with bone marrow stromal cells. The bone marrow stromal cells provide growth and survival signals, thereby promoting the deve
Externí odkaz:
https://doaj.org/article/9ae3e3ccba2e4821b3f01ffba88946f8
Autor:
Yao Yao, Shuhui Deng, Jessica Fong Ng, Mei Yuan, Chandraditya Chakraborty, Vera JoyWeiler, Nikhil Munshi, Mariateresa Fulciniti
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Multiple myeloma (MM) is a plasma cell malignancy considered incurable despite the recent therapeutic advances. Effective targeted therapies are therefore needed. Our previous studies proved that inhibiting CDK7 impairs the cell cycle and metabolic p
Externí odkaz:
https://doaj.org/article/31706248e88f466b907a382739aca66d
Autor:
Debasmita Dutta, Jiye Liu, Kenneth Wen, Keiji Kurata, Mariateresa Fulciniti, Annamaria Gulla, Teru Hideshima, Kenneth C. Anderson
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Bortezomib (BTZ) is a standard-of-care treatment in multiple myeloma (MM); however, adverse side effects and development of resistance limit its long term benefit. To improve target specificity, therapeutic efficacy, and overcome resistance,
Externí odkaz:
https://doaj.org/article/7d50b6f504af47028426c84f41e90866
Autor:
Rao Prabhala, William E. Pierceall, Mehmet Samur, Lakshmi B. Potluri, Kevin Hong, Teresa Peluso, Srikanth Talluri, Angela Wang, Aishwarya Katiki, Sahan D. Vangala, Michael Buonopane, Vaishnavi Bade, Hannah Seah, Arthur Krogman, Sanika Derebail, Mariateresa Fulciniti, Suzan B. Lazo, Paul Richardson, Kenneth Anderson, Jill Corre, Herve Avet-Loiseau, Anjan Thakurta, Nikhil Munshi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMultiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such as pomalidomide and lenalidomide, have been found to improve the immune profile,
Externí odkaz:
https://doaj.org/article/ec54f456dc72424aa10934daa1704895
Autor:
Anil Aktas Samur, Mariateresa Fulciniti, Herve Avet-Loiseau, Michael A. Lopez, Sanika Derebail, Jill Corre, Stephane Minvielle, Florence Magrangeas, Philippe Moreau, Kenneth C. Anderson, Giovanni Parmigiani, Mehmet K. Samur, Nikhil C. Munshi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 12, Pp 1-11 (2022)
Abstract Splicing changes are common in cancer and are associated with dysregulated splicing factors. Here, we analyzed RNA-seq data from 323 newly diagnosed multiple myeloma (MM) patients and described the alternative splicing (AS) landscape. We obs
Externí odkaz:
https://doaj.org/article/8f433518944f46019120b39f11b9a13b
Autor:
Eugenio Morelli, Zachary R. Hunter, Mariateresa Fulciniti, Annamaria Gullà, Ida Daniela Perrotta, Valeria Zuccalà, Cinzia Federico, Giada Juli, Martina Manzoni, Domenica Ronchetti, Enrica Romeo, Maria Eugenia Gallo Cantafio, Debora Soncini, Lorenza Maltese, Marco Rossi, Aldo M. Roccaro, Michele Cea, Pierfrancesco Tassone, Antonino Neri, Steven C. Treon, Nikhil C. Munshi, Giuseppe Viglietto, Nicola Amodio
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-6 (2022)
Abstract Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy for treating a variety of human diseases including cancer. Here, we show that GPER1 is significantly upregulated in tumor cells from different coh
Externí odkaz:
https://doaj.org/article/8e2f2cc9b27d46db8aa9ce4fa5663b16
Autor:
Mehmet Kemal Samur, Mariateresa Fulciniti, Anil Aktas Samur, Abdul Hamid Bazarbachi, Yu-Tzu Tai, Rao Prabhala, Alejandro Alonso, Adam S. Sperling, Timothy Campbell, Fabio Petrocca, Kristen Hege, Shari Kaiser, Hervé Avet Loiseau, Kenneth C. Anderson, Nikhil C. Munshi
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
Relapse following BCMA targeted CAR T-cell therapy is frequently observed in patients with multiple myeloma (MM). Here, by single cell transcriptome profiling on serially collected bone marrow samples, the authors report biallelic loss of BCMA as the
Externí odkaz:
https://doaj.org/article/d60d813fb4064441b48a7626818c3ce7
Autor:
Debora Soncini, Claudia Martinuzzi, Pamela Becherini, Elisa Gelli, Samantha Ruberti, Katia Todoerti, Luca Mastracci, Paola Contini, Antonia Cagnetta, Antonella Laudisi, Fabio Guolo, Paola Minetto, Maurizio Miglino, Sara Aquino, Riccardo Varaldo, Daniele Reverberi, Matteo Formica, Mario Passalacqua, Alessio Nencioni, Antonino Neri, Mehmet K. Samur, Nikhil C. Munshi, Mariateresa Fulciniti, Roberto M. Lemoli, Michele Cea
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Identification of novel vulnerabilities in the context of therapeutic resistance is emerging as a key challenge for cancer treatment. Recent studies have detected pervasive aberrant splicing in cancer cells, supporting its targeting for novel therape
Externí odkaz:
https://doaj.org/article/309434a4c8104d54bfdbb57fcf74b015
Autor:
Francesco Maura, Niccoló Bolli, Nicos Angelopoulos, Kevin J. Dawson, Daniel Leongamornlert, Inigo Martincorena, Thomas J. Mitchell, Anthony Fullam, Santiago Gonzalez, Raphael Szalat, Federico Abascal, Bernardo Rodriguez-Martin, Mehmet Kemal Samur, Dominik Glodzik, Marco Roncador, Mariateresa Fulciniti, Yu Tzu Tai, Stephane Minvielle, Florence Magrangeas, Philippe Moreau, Paolo Corradini, Kenneth C. Anderson, Jose M. C. Tubio, David C. Wedge, Moritz Gerstung, Hervé Avet-Loiseau, Nikhil Munshi, Peter J. Campbell
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Multiple myeloma evolves continuously. Here the authors chronologically reconstruct driver events in multiple myeloma, noting a limited repertoire of initiating driver events that shape the evolutionary trajectory of the disease.
Externí odkaz:
https://doaj.org/article/a38608a486ef471e8da57b4ab94d19b3